CRNX
Crinetics Pharmaceuticals, Inc.
$42.03
-0.20 (-0.47%)
At close · Jul 6
Market Cap
$4.43B
Shares
105,440,208
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$42.03
Open$42.03
Day$41.39–44.11
52W$25.83–57.99
Avg vol 30d1.3M
Short int12.9M · 12.2% float · 13.2d
Short vol57%
Last earningsMay 7, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 7
Equibles Rating
blended score · not investment advice
Overall
Sell
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+0% above
+
Price vs 50-day avg
+14% above
−
RSI (14)
71 · overbought
+
MACD trend
positive
◦
52-week position
50% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $37 › 200d $42 — 200d above 50d
−
Institutional flow
3 of 244 funds reported for Jun 30 · net -16 sh shares
−
Insider flow
Net -$3.4M over 90 days · 100% sells
−
Short interest
12.19% of float · ▲ +1.7% MoM · 13.2 days cover
◦
Volume signal
High volume on a down day — possible exhaustion
+
Institution breadth
244 holders — near 3-yr high, broad support
Fundamentals
Weak
−
Revenue growth
−74% Y/Y
−
EPS growth
−34% Y/Y
−
Free cash flow
$-383.7M
+
Balance sheet
net cash $101.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 6, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Guidance & track record
Latest guidance
· from the 8-K filed May 7, 2026
Non-GAAP operating expenses
· 2026
Non-GAAP
Initiated
$480M – $520M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+0% above
Bullish
Price vs 50-day avg
+14% above
Bullish
RSI (14)
71 · overbought
Bearish
MACD trend
positive
Bullish
52-week position
50% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $37 › 200d $42 — 200d above 50d
Institutional flow
Distributing
3 of 244 funds reported for Jun 30 · net -16 sh shares
Insider flow
Distributing
Net -$3.4M over 90 days · 100% sells
Short interest
Rising
12.19% of float · ▲ +1.7% MoM · 13.2 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Multi-yr high
244 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $26
Now $42 · 50%
52-wk high $58
vs 200-day avg +0%
vs 50-day avg +14%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Enrollment forms | 232 | Q1 2026 | — |
| Patients on reimbursed therapy | 70% | end of Q1 2026 | — |
| first quarter prescriptions from patients reinitiating therapy after discontinuing prior treatme | 15% | Q1 FY2026 call | — |
| new patient enrollment forms | 232 | Q1 FY2026 call | — |
| patients on therapy reimbursed | 70% | end of Q1 FY2026 call | — |
| placebo-adjusted IGF-1 normalization (paltusotine) | 79.7% | PATHFNDR-1 analysis call | — |
| treatment-naive patients share of total enrollments | 15% | Q1 FY2026 call | — |
| unique prescribers | 263 | as of March 31 call | — |
| Most prior authorization duration | 12 | Q4 FY2025 | — |
| U.S.-based open-label extension enrollment forms | 22 | Q4 FY2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CRNX
this stock
Crinetics Pharmaceuticals, Inc.
|
$4.43B | -9.7% | -74.1% | — | 12.2% |
|
AKTX
Akari Therapeutics Plc
|
$998.08B | -5.7% | — | — | 0.0% |
|
ONC
BeOne Medicines Ltd.
|
$488.96B | +1.9% | +22179.2% | 995.1 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$134.41B | +16.8% | +46.2% | 31.4 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.33B | -15.7% | +20.8% | 16.1 | 3.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CRNX | +14.5% | +21.4% | -21.1% | +12.3% | -9.7% |
| SPY | +3.1% | -0.8% | +8.2% | +0.6% | +10.2% |
| vs SPY | +11.5% | +22.1% | -29.3% | +11.7% | -19.9% |